JP2023532128A5 - - Google Patents

Info

Publication number
JP2023532128A5
JP2023532128A5 JP2022581398A JP2022581398A JP2023532128A5 JP 2023532128 A5 JP2023532128 A5 JP 2023532128A5 JP 2022581398 A JP2022581398 A JP 2022581398A JP 2022581398 A JP2022581398 A JP 2022581398A JP 2023532128 A5 JP2023532128 A5 JP 2023532128A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
alkyl
composition according
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532128A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040171 external-priority patent/WO2022006447A1/en
Publication of JP2023532128A publication Critical patent/JP2023532128A/ja
Publication of JP2023532128A5 publication Critical patent/JP2023532128A5/ja
Pending legal-status Critical Current

Links

JP2022581398A 2020-07-02 2021-07-01 抗がん作用を有する化合物 Pending JP2023532128A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047612P 2020-07-02 2020-07-02
US63/047,612 2020-07-02
PCT/US2021/040171 WO2022006447A1 (en) 2020-07-02 2021-07-01 Compounds having anticancer activity

Publications (2)

Publication Number Publication Date
JP2023532128A JP2023532128A (ja) 2023-07-26
JP2023532128A5 true JP2023532128A5 (https=) 2024-07-09

Family

ID=79314944

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023524493A Pending JP2023535527A (ja) 2020-07-02 2021-07-01 抗菌活性を有する化合物
JP2022581398A Pending JP2023532128A (ja) 2020-07-02 2021-07-01 抗がん作用を有する化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023524493A Pending JP2023535527A (ja) 2020-07-02 2021-07-01 抗菌活性を有する化合物

Country Status (7)

Country Link
US (2) US20230295164A1 (https=)
EP (2) EP4175953A4 (https=)
JP (2) JP2023535527A (https=)
CN (2) CN115867354B (https=)
AU (2) AU2021299504A1 (https=)
CA (2) CA3183770A1 (https=)
WO (2) WO2022006432A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963959B2 (en) * 2021-08-17 2024-04-23 Southwest Research Institute Inhibitors for coronavirus
WO2024077235A2 (en) * 2022-10-07 2024-04-11 The Trustees Of Princeton University Dihydrofolate reductase inhibitors for anti-biotic resistant infections
CN118047780A (zh) * 2022-11-09 2024-05-17 中国医学科学院药物研究所 一类喹唑啉杂环化合物及其抗感染和抗肿瘤的应用
CN119661535B (zh) * 2023-09-21 2026-03-20 中国医学科学院药物研究所 7H-吡咯并[3,2-f]喹唑啉衍生物及其抗感染应用
WO2025194625A1 (zh) * 2024-03-22 2025-09-25 深圳湾实验室坪山生物医药研发转化中心 结核病的预防与治疗
WO2025195460A1 (zh) * 2024-03-22 2025-09-25 深圳湾实验室坪山生物医药研发转化中心 稠环衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45427B1 (en) * 1976-07-09 1982-08-25 American Home Prod Pyrrold 3,2if quinazoline-1,3-diamine and related compounds
US4118561A (en) * 1977-04-06 1978-10-03 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
US7253177B2 (en) * 2004-10-22 2007-08-07 United States Of America As Represented By The Secretary Of The Army Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives
US9920058B2 (en) * 2013-05-06 2018-03-20 Georgia Tech Research Corporation Molecules with potent DHFR binding affinity and antibacterial activity
EP3010923A4 (en) * 2013-06-20 2016-12-14 Univ Oregon Health & Science PYRROLOCHINAZOLINVERBINDUNGEN
WO2015173802A1 (en) * 2014-05-11 2015-11-19 Tel Hashomer Medical Research Infrastructure And Services Ltd. Par-1 based therapeutic conjugates and uses thereof
US11077109B2 (en) * 2017-08-01 2021-08-03 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
US20210161900A1 (en) * 2018-04-30 2021-06-03 Duke University Compositions and methods for the treatment of senescent tumor cells
CN114514230A (zh) * 2019-08-20 2022-05-17 希望之城 Mettl16抑制剂及其用途

Similar Documents

Publication Publication Date Title
JP2023532128A5 (https=)
JP2021523221A5 (https=)
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
RU2481346C2 (ru) Ингибиторы фосфатидилинозитол-3-киназы
JP2012508252A5 (https=)
JP2021534124A5 (https=)
JP2021516231A5 (https=)
RU2004111979A (ru) Производные 1н-имидазола, обладающие св1-агонистической, частичной св1-агонистической или св1-антагонистической активностью
RU2012116584A (ru) Лизинспецифические ингибиторы деметилазы-1 и их применение
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2015520143A5 (https=)
JP2011509309A5 (https=)
JP2017528498A5 (https=)
JP2015517574A5 (https=)
CA2474192A1 (en) Nicotinamide derivates useful as p38 inhibitors
AR038914A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion para fabricar un medicamento
JP2011526913A5 (ja) キナゾリン化合物及び同化合物を含む治療薬
JP2021524482A5 (https=)
RU2013112871A (ru) Соединения для лечения рака
JP2023504542A5 (https=)
JP2023538524A5 (https=)
JP2020502116A5 (https=)
CA2479363A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
JP2006520761A5 (https=)